Skip to content

Study · Case report or series · n = 1 · 2022

1 result

An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption.

Kyriakos G, Diamantis E, Memi E, Elefsiniotis I

Cureus23 Jan 2022Cited by 7 (Europe PMC)

PMID35223310 (opens in a new tab)PMCIDPMC8864188 (opens in a new tab)DOI10.7759/cureus.21536 (opens in a new tab)PepBankPUB-35223310
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Dulaglutide is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist that has shown a durable glycemic efficacy as well as beneficial effects on body weight and major adverse cardiovascular events (MACE) outcomes, making it an important option for the treatment of type 2 diabetes. Common side effects of dulaglutide include nausea, diarrhea, and abdominal distension, and these are usually mild to moderate in severity and tend to diminish over time. Morbilliform drug eruptions to dulaglutide are very rare, with only one case reported until now. We report another case of dulaglutide-morbilliform drug eruption to alert the attending physicians that dulaglutide-related adverse skin reactions should be kept in mind as generalized use of dulaglutide and other GLP-1 receptor agonists are expected to remain in widespread clinical use in the future.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A case report described a dulaglutide-related morbilliform drug eruption.

    In plain wordsOne case report described a measles-like drug rash linked to dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableMorbilliform drug eruption
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report another case of dulaglutide-morbilliform drug eruption

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.